MiSight® Spectacle Lenses

MiSight® Spectacle Lenses are the only myopia management spectacle lens that has been shown to be effective in a clinical study on children as young as 6 years old.1

Let’s build a brighter future for your child.

 

The importance of treating myopia, not just correcting vision.

 

Myopia (nearsightedness) is more than just blurry vision. It’s a chronic, progressive disease, growing in both prevalence and severity.3  

It can stop children doing the things they love4-9 and limit future career options.10 Myopia can also progress rapidly, particularly in young children,11 and lead to more severe eye conditions in later life.12-15

Breakthrough research has shown that contrast signals in modern artificial environments may cause young eyes to grow longer and become more myopic.‡16

 

 

New MiSight® Spectacle Lenses.
Act now to help change your child’s future vision.§1

 

girl wearing glasses

MISIGHT® SPECTACLE LENSES SLOW AVERAGE MYOPIA WORSENING BY UP TO
75%
after 12 months of wear
across diverse populations
of children. ¶17,18

 

Over time, excessive eye growth leads to worsening myopia. So, the sooner myopia is managed, the better the long-term eye health and vision outcomes are expected to be.19

 

New MiSight® Spectacle Lenses. 

Powered by Diffusion Optics TechnologyTM .

 

Unlike traditional spectacles, MiSight® Spectacle Lenses’ unique Diffusion Optics TechnologyTM scatters light. This helps slow abnormal growth in young eyes which can slow the worsening of myopia.18  

glasses

 

Ready to take on myopia? 

 

You don’t have to settle for just correcting vision which may worsen over time. With MiSight® Spectacle Lenses, you can take positive action.†1 

 

Ask your Eye Care Professional about trying MiSight® Spectacle Lenses for your child today.

 

 

 

Unsure which products are best for you?

Take this four question quiz to discover which of our products may best fit your needs.

Find Your Lens

*Compared to control spectacle lenses. Analysis based on parent responses to in-office question, "Does your child remove their spectacles for any near vision activities?" (n=51 test, n=62 control). For the full study cohort, reduction in progression of spherical equivalent refraction baseline over 24 months was 47% on average.

†Reduction in progression of spherical equivalent refraction and axial length from baseline over 12 months was 74% and 50%, respectively (p<0.0001).

‡Definition of contrast signals in modern artificial environments - Modern urban lifestyle: high contrast over the entire viewing area. Children are exposed to artificial contrast in the modern visual environment contributing to myopia development.

§Versus 65% of control subjects, p=0.0032 (n=74 test, n=87 control).

¶Based on a North American patient population aged 6–10 years (least-squared means) and a Chinese patient population aged 6–13 years (unadjusted means). Significant progression defined as >0.25 D change from baseline.

†Reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average, respectively (p<0.0041).

INDICATION: MiSight® Spectacle Lenses are indicated for the correction of refractive ametropia (myopia and/or astigmatism) and for the reduction in the rate of myopic progression in phakic children who are aged 6 to 13 years old with non-diseased eyes. MiSight® Spectacle Lenses should be worn constantly for all activities except for those outlined in WARNINGS, within the legal manufacturer’s Instructions for Use (a minimum of 10 hours per day).

Regulatory indications of and access to interventions for slowing myopia progression vary by country. CooperVision does not endorse off-label prescribing.

References:

1. SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n = 256, 14 North American sites). 

2. Rappon J, Neitz J, Neitz M, Young G, Chalberg T. CYPRESS 12-month Results: Safety and Efficacy from a Pivotal Study of Novel Spectacle Lenses Designed to Reduce Myopia Progression. Optometry and Vision Science. 2020;97:E-abstract 200036.

3. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. 

4. Ma X, Zhou Z, Yi H, Pang X, Shi Y, Chen Q, Meltzer ME, le Cessie S, He M, Rozelle S, Liu Y, Congdon N. Effect of providing free glasses on children's educational outcomes in China: cluster randomized controlled trial. BMJ. 2014 Sep 23;349:g5740.

5. Jan C, Li S, Kang M, et al. Association of visual acuity with educational outcomes: a prospective cohort study. British Journal of Ophthalmology 2019;103:1666-1671.

6. Yadav R, et al. Vision Related Quality of Life, Sports Activities and Academic Performance Among Myopic School Going children: A Cross Sectional Study. African Journal of Biomedical Research 2024; 27(1S), 2228-2231.

7. Sankaridurg P, Tahhan N, Kandel H, et al. IMI Impact of myopia. Invest Ophthalmol Vis Sci. 2021;62(5):2. pg 6.

8. Shams N, Mobaraki H, Kamali M, Jafarzadehpour E. Comparison of quality of life between myopic patients with spectacles and contact lenses, and patients who have undergone refractive surgery. J Curr Ophthalmol. 2015 Nov 17;27(1-2):32-6.

9. Pan C-W, Ramamurthy D & Saw S-M. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt 2012, 32, 3-16.

10. Vision standards and requirements. Association of Optometrists. (n.d.). Retrieved December 20, 2021, from https://www.aop.org.uk/advice-and-support/clinical/vision-standards [Note: Local markets should check local standards for vision performance and update the reference as appropriate. The Global version references UK standards.

11. K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306. 

12. Xu L et al. High myopia and glaucoma susceptibility, the Beijing Eye Study. Ophthalmology. 2007;114(2):216-20.

13. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. PRER 2013;31(6):622-60.

14. Younan C, et al. Myopia and incident cataract and cataract surgery: the blue mountains eye study. IVOS 2002;43(12):3625-3632.

15. Chen SJ, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. IOVS.

16. Neitz M et al. Insight from OPN1LW Gene Haplotypes into the Cause and Prevention of Myopia. Genes. 2022;13(6):942.

17. Laughton D., et al. Control of myopia using diffusion optics spectacle lenses in a Chinese population: 12-month results. 2025 ARVO poster presentation. 24-month, randomized and controlled clinical trial across 5 Chinese hospital sites, evaluating DOT spectacle lenses (n=128) versus control standard single vision spectacle lenses (n=58) in myopic children aged 6–13.

18. Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol. 2023;107:1709-1715.

19. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci. 2019 Jun;96(6):463-465.